![Event-free survival (EFS) and overall survival (OS) according to risk... | Download Scientific Diagram Event-free survival (EFS) and overall survival (OS) according to risk... | Download Scientific Diagram](https://www.researchgate.net/publication/339340909/figure/fig4/AS:958472770310157@1605529124751/Event-free-survival-EFS-and-overall-survival-OS-according-to-risk.png)
Event-free survival (EFS) and overall survival (OS) according to risk... | Download Scientific Diagram
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/42242196-7947-4953-8385-0cd868f209d3/gr1.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study | British Journal of Cancer Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2017.462/MediaObjects/41416_2018_Article_BFbjc2017462_Fig1_HTML.jpg)
Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study | British Journal of Cancer
![Neurologic-Event-Free Survival (NEFS): A New Endpoint for Severe Combined Immunodeficiency (SCID) Patients Diagnosed by Newborn Screening (NBS) and Treated with Hematopoietic Cell Transplantation (HCT) - Biology of Blood and Marrow Transplantation Neurologic-Event-Free Survival (NEFS): A New Endpoint for Severe Combined Immunodeficiency (SCID) Patients Diagnosed by Newborn Screening (NBS) and Treated with Hematopoietic Cell Transplantation (HCT) - Biology of Blood and Marrow Transplantation](https://www.astctjournal.org/cms/attachment/2088318892/2074934328/ybbmt54475-fig-0001.jpg)
Neurologic-Event-Free Survival (NEFS): A New Endpoint for Severe Combined Immunodeficiency (SCID) Patients Diagnosed by Newborn Screening (NBS) and Treated with Hematopoietic Cell Transplantation (HCT) - Biology of Blood and Marrow Transplantation
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/8b10cd73-be2f-4363-ba25-eb395b6c06c4/gr2_lrg.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2020/jco.2020.38.issue-26/jco.19.03114/20200825/images/large/jco.19.03114t2.jpeg)
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology
ASH 2022: FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3
![MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients](https://www.spandidos-publications.com/article_images/ol/24/4/ol-24-04-13450-g03.jpg)
MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients
![Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma](https://www.frontiersin.org/files/Articles/835389/fonc-12-835389-HTML/image_m/fonc-12-835389-g002.jpg)
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
![Cancers | Free Full-Text | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study Cancers | Free Full-Text | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study](https://pub.mdpi-res.com/cancers/cancers-14-02215/article_deploy/html/images/cancers-14-02215-ag-550.jpg?1651227523)
Cancers | Free Full-Text | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure1-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
![Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-67147-7/MediaObjects/41598_2020_67147_Fig1_HTML.png)
Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports
![Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation](https://www.astctjournal.org/cms/attachment/7b390ded-6c92-4578-8079-4e858709eaf2/ybbmt54468-fig-0001_lrg.jpg)
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation
![Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download](https://images.slideplayer.com/30/9505354/slides/slide_4.jpg)
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
![Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/312303406/figure/fig1/AS:625531582177282@1526149759970/Kaplan-Meier-plot-of-event-free-survival-EFS-and-overall-survival-OS-A-EFS-in-all.png)
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram
![A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12872-020-01502-4/MediaObjects/12872_2020_1502_Fig1_HTML.png)
A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text
![Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients - ScienceDirect Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497119434125-fx1.jpg)
Prognostic Index for Predicting Overall Survival and Event-Free Survival In Total Therapy 3 Patients - ScienceDirect
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology
![Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-8/jco.21.01548/20220227/images/keyimage.jpg)